[go: up one dir, main page]

WO2005113013A3 - Compositions de vmn et methodes d'utilisation de ces compositions pour le traitement du cancer - Google Patents

Compositions de vmn et methodes d'utilisation de ces compositions pour le traitement du cancer Download PDF

Info

Publication number
WO2005113013A3
WO2005113013A3 PCT/IL2005/000518 IL2005000518W WO2005113013A3 WO 2005113013 A3 WO2005113013 A3 WO 2005113013A3 IL 2005000518 W IL2005000518 W IL 2005000518W WO 2005113013 A3 WO2005113013 A3 WO 2005113013A3
Authority
WO
WIPO (PCT)
Prior art keywords
ndv
methods
cancer
compositions
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2005/000518
Other languages
English (en)
Other versions
WO2005113013A2 (fr
Inventor
Zichria Zakay-Rones
Amos Panet
Evgeniya Greenbaum
Eithan Galun
Arnold I Freeman
Linda Rasooly
Charles S Irving
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravir Management LP
Original Assignee
Theravir Management LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravir Management LP filed Critical Theravir Management LP
Publication of WO2005113013A2 publication Critical patent/WO2005113013A2/fr
Publication of WO2005113013A3 publication Critical patent/WO2005113013A3/fr
Priority to US11/561,510 priority Critical patent/US7615209B2/en
Priority to IL179420A priority patent/IL179420A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes destinées à induire la régression d'une tumeur chez un sujet, qui consistent à administrer audit sujet une composition pharmaceutique comprenant une souche lentogène du virus de la maladie de Newcastle (VMN). Une souche virale de VMN préférée pouvant induire la régression d'une tumeur chez un sujet est une souche clonale de VMN appelée HUJ. Les méthodes de l'invention sont particulièrement utiles pour induire la régression de tumeurs chez des patients insensibles aux traitements classiques contre le cancer.
PCT/IL2005/000518 2001-09-12 2005-05-19 Compositions de vmn et methodes d'utilisation de ces compositions pour le traitement du cancer Ceased WO2005113013A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/561,510 US7615209B2 (en) 2001-09-12 2006-11-20 Compositions of NDV and methods of use thereof for treatment of cancer
IL179420A IL179420A0 (en) 2004-05-20 2006-11-20 Compositions of ndv and methods of use thereof for treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57247504P 2004-05-20 2004-05-20
US60/572,475 2004-05-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/561,510 Continuation US7615209B2 (en) 2001-09-12 2006-11-20 Compositions of NDV and methods of use thereof for treatment of cancer

Publications (2)

Publication Number Publication Date
WO2005113013A2 WO2005113013A2 (fr) 2005-12-01
WO2005113013A3 true WO2005113013A3 (fr) 2006-05-18

Family

ID=35428863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000518 Ceased WO2005113013A2 (fr) 2001-09-12 2005-05-19 Compositions de vmn et methodes d'utilisation de ces compositions pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2005113013A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1744780B1 (fr) 2004-04-27 2013-08-07 Wellstat Biologics Corporation Traitement de cancers utilisant des virus et des camptothecines
ATE540698T1 (de) 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
EP2327764B1 (fr) 2009-11-30 2011-12-28 United Cancer Research Institute Nouveau clone du virus de la maladie de Newcastle, sa fabrication et son application dans le traitement médical du cancer
US20130202558A1 (en) * 2012-02-01 2013-08-08 James C. Phillips Recombinant replication competent oncolytic viruses and methods of use thereof for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FREEMAN ET AL: "Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.", MOLECULAR THERAPY, November 2005 (2005-11-01) *
PHUANGSAB ET AL: "Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local systemic administration.", CANCER LETTERS., vol. 172, October 2001 (2001-10-01), pages 27 - 36 *
SCHIRRIRMACHER ET AL: "Antitumor effects of Newcastle Disease Virus in vivo.", LOCAL VERSUS SYSTEMIC EFFECTS., vol. 18, May 2001 (2001-05-01), pages 945 - 952, XP002969166 *

Also Published As

Publication number Publication date
WO2005113013A2 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2012142529A3 (fr) Souches clonales de virus atténués de la vaccine et leurs procédés d'utilisation
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
WO2021228106A1 (fr) Virus oncolytique en association avec un inhibiteur de point de contrôle immunitaire pour le traitement de tumeurs
PH12017501461B1 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2010111018A8 (fr) Conjugues anticorps-medicament (adc) se liant aux proteines 24p4c12
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
UA109108C2 (uk) Антитіло до pd-l1 та його застосування для посилення функції t-клітин
PH12012501545B1 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
WO2009060281A3 (fr) Analogues d'oligoribonucléotides immunostimulants contenant des fractions oligophosphates modifiées
NZ606765A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
JP2020521797A5 (fr)
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
JP2015533376A5 (fr)
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
JP2013047276A (ja) ウイルスおよびカンプトテシン類を使用する癌の処置
Kumar et al. Therapeutic approach against 2019-nCoV by inhibition of ACE-2 receptor
MX2012004409A (es) Proteina recombinante de humano cc10 para el tratamiento de la influenza.
WO2003022202A3 (fr) Compositions et methodes pour le traitement du cancer
WO2005113013A3 (fr) Compositions de vmn et methodes d'utilisation de ces compositions pour le traitement du cancer
JP5190958B2 (ja) ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置
WO2010077364A3 (fr) Stimulateurs d'angiogenèse générés par un accident vasculaire cérébral et leurs utilisations
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 179420

Country of ref document: IL

Ref document number: 11561510

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 11561510

Country of ref document: US

122 Ep: pct application non-entry in european phase